Alivus Life Sciences Intrinsic Value
ALIVUS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹952.60 | ₹762.08 - ₹1143.12 | +5.0% | EPS: ₹43.30, Sector P/E: 22x |
| Book Value Method | asset | ₹2253.60 | ₹2028.24 - ₹2478.96 | +148.5% | Book Value/Share: ₹1126.80, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1813.70 | ₹1632.33 - ₹1995.07 | +100.0% | Revenue/Share: ₹1010.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1813.70 | ₹1632.33 - ₹1995.07 | +100.0% | EBITDA: ₹785.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1207.07 | ₹965.66 - ₹1448.48 | +33.1% | CF Growth: 0.3%, Discount: 15% |
| PEG Ratio Method | growth | ₹272.06 | ₹244.85 - ₹299.27 | -70.0% | EPS Growth: 5.0%, Fair P/E: 4.0x |
| Growth Adjusted P/E | growth | ₹663.29 | ₹596.96 - ₹729.62 | -26.9% | Revenue Growth: 4.2%, Adj P/E: 15.3x |
| ROE Based Valuation | profitability | ₹1813.70 | ₹1632.33 - ₹1995.07 | +100.0% | ROE: 18.8%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1047.75 | ₹942.98 - ₹1152.53 | +15.5% | EPS: ₹43.30, BVPS: ₹1126.80 |
| Dividend Yield Method | dividend | ₹272.06 | ₹244.85 - ₹299.27 | -70.0% | DPS: ₹5.00, Target Yield: 2.5% |
Want to compare with current market value? Check ALIVUS share price latest .
Valuation Comparison Chart
ALIVUS Intrinsic Value Analysis
What is the intrinsic value of ALIVUS?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Alivus Life Sciences (ALIVUS) is ₹1207.07 (median value). With the current market price of ₹906.85, this represents a +33.1% variance from our estimated fair value.
The valuation range spans from ₹272.06 to ₹2253.60, indicating ₹272.06 - ₹2253.60.
Is ALIVUS undervalued or overvalued?
Based on our multi-method analysis, Alivus Life Sciences (ALIVUS) appears to be trading below calculated value by approximately 33.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 18.83 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.21 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 18.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 30.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.74x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Alivus Life Sciences
Additional stock information and data for ALIVUS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹392 Cr | ₹84 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹414 Cr | ₹356 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹306 Cr | ₹233 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹598 Cr | ₹537 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹388 Cr | ₹354 Cr | Positive Free Cash Flow | 8/10 |